Neutralizing antibodies for SARS-CoV-2 prevent the virus from entering healthy cells and directly correlate to a person’s level of protection from future infection. Read how IMMUNO-COV assay accurately measures the level of SARS-CoV-2-neutralizing antibodies in vaccinated individuals.

As vaccines continue to be rolled out across the country, it is important for the public to understand that herd immunity cannot be validated by inoculation rates alone.

After a devastating year grappling with the COVID-19 pandemic, the future is looking brighter with the rollout of highly effective vaccines.  But while the number of people vaccinated is steadily increasing, unfortunately their immunity to the virus will inevitably wane over time, raising important questions for healthcare businesses, providers and the public at large: How long will vaccines provide protective immunity?  Are vaccines working as expected in each person? What impact do viral variations have on vaccine efficacy?

Next year, people are likely to need an annual COVID-19 vaccination just like they need an annual flu shot.
That prediction is made by researchers at six of Australia’s leading medical research institutions, based
upon their study of the levels of neutralizing antibodies needed to confer protection against COVID-19.
The detailed paper appeared in a medRxiv preprint.

During the COVID-19 pandemic, people have been separated from their friends and family due to the need for social distancing and lockdowns. Now, as efforts to vaccinate people against COVID-19 are well underway, there is hope that everyone will be reunited with their loved ones again soon.

Got a positive COVID-19 test? Take a deep breath and use this guide to make sense of the situation.

Dr. Rianna Vandergaast’s journey into the sciences began with a simple, seventh grade science project. Now, she’s a lead researcher in COVID-19 neutralizing antibody testing.

Centers for Disease Control and Prevention (CDC) guidelines have been updated stating that fully vaccinated people may visit unvaccinated people from a single household who are at low risk for severe COVID-19.

Vyriad, a Rochester biotech firm founded by Mayo Clinic researchers, is developing an oral vaccine for the coronavirus that could be used as a booster in the months after the initial wave of vaccinations.

Company releases data from its latest improved IMMUNO-COV™️ quantitative neutralizing antibody test. Data shows former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months, and assay shows no guarantee that severe disease results in higher levels of antibody protection. The manuscript is available on medRxiv and has been submitted for additional publication following scientific peer review.

Vyriad, a scientific research lab based in Rochester, Minnesota, started working on a COVID-19 vaccine early last year and lab testing shows its delivery method and properties could give people immunity to the virus.

On January 8, the Food and Drug Administration (FDA) warned of the potential for coronavirus tests to produce false negative results because of genetic variants of the SARS-CoV-2 virus. This announcement comes after a new COVID-19 strain called B.1.1.7 emerged in the United Kingdom, which has also been detected in the United States.

The Observer, in advance of the JP Morgan Healthcare Conference, names Imanis Life Sciences and sister company Vyriad as one of the hottest health startups from flyover country of 2021.

Imanis Life Sciences Principal Scientist, Rianna Vandergaast, Ph.D talks to Authority Magazine about lessons learned about leadership and the principles that guide her in the world of STEM.

Imanis Life Sciences CEO and co-founder, Dr. Stephen Russell, talks to Authority Magazine about Heroes – what makes a hero, heroes in his own life, and heroes amid the current world climate.

As the long-awaited COVID-19 vaccine distribution process begins in the United States, there’s plenty of deliberation around who gets the vaccine, and when. Much attention has been brought to the people who have already been infected with COVID-19. Should they also get the vaccine? Don’t people who have had COVID-19 have immunity?

While many wait for news of a COVID-19 vaccine in the United States, a Rochester company says it has created something that can help figure out if you can fight the virus off on your own.

How immune are you? That’s the question developers of a new COVID-19 antibody test or assay hope to answer for patients and doctors.

So, what’s your titer? That question, still strange sounding, may soon become important as vaccines bring about the endgame for COVID-19.

High-throughput clinical assay detects and quantifies SARS-CoV-2 neutralizing antibodies